Figure 1

Spexin levels in the plasma. (A) Circulating levels of spexin were measured by ELISA using plasma samples from normal-weight (n = 50) and obese people without (n = 66) and with diabetes (n = 69) at baseline. 2-way ANOVA test was used to determine significance of difference in means between the groups. (B) Obese participants without diabetes were segregated into 2 groups, metabolically healthy obese (MHO) and metabolically unhealthy obese (MUO) based on the Adult Treatment Panel-III (NCEP-ATPIII guideline) criteria for metabolic syndrome components¹⁸ including the following criteria: (1) TG ≥ 150 mg/dl; (2) HDL-C < 40 mg/dl for men and < 50 mg/dl for women; (3) BP ≥ 130/85 mm Hg and (4) FBG ≥ 100 mg/dl. Nonparametric Wilcoxon test was used to determine significance of difference in means between the two groups. (C) Good and poor glycaemic control participant classification are based on HbA1c levels. Nonparametric Wilcoxon test was used to determine significance of difference in means between the two groups.